PML risk education; keeping it simple. #MSBlog #MSResearch
"I am now aware that most MSers don't want to wade through detailed slide decks to get their heads around the risks and benefits of natalizumab therapy. We therefore asked Alison Thomson, a designer in our group to come up with something simple; our very own visual guide. We have now tested this visual guide in our infusion unit and performed a clinical audit to see if the tool can make a difference."
The following are the headline results of our audit:
- Overall the degree of knowledge of the risk of PML increases
after using the tool. However, the knowledge decreased at 6 weeks.
- Before the MSers were shown the tool, only 20% got the answer correct to "Do you know how many cases of PML
have been reported so far?" asked after the tool was used 90% got it
correct and when asked 6 weeks later only 40% got it correct.
- All MSers said they were aware of the risk of PML
when on natalizumab but only 30% knew the overall risk of PML. This was
increased to 40% after use of the tool.
- Importantly, all MSers see the same nurse for their
infusions and all feel that the implications of the JC virus are
adequately explained to them.
- All people said they were satisfied with the service they are
receiving at Barts Health NHS Trust.
"Do you think keeping it simple with this simple visual guide is an improvement on the detailed monthly slide shows I have been posted on the blog?"
Labels: guide, Natalizumab, PML, PML Risk update, Tysabri, visual guide